文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽-1受体激动剂与2型糖尿病患者的胃肠道癌症风险

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-06-05

基于TriNetX研究网络的回顾性队列研究,比较GLP-1受体激动剂与其他降糖药新使用者的胃肠道癌症风险。经倾向性评分匹配后,GLP-1受体激动剂使用与整体胃肠道癌症风险显著降低相关,与胰岛素相比风险降低最明显。

要点

  • GLP-1受体激动剂使用与整体胃肠道癌症风险显著降低相关。
  • 与胰岛素相比保护作用最明显,aHR为0.29(95%CI 0.23,0.37)。
  • 与二甲双胍、磺脲类、噻唑烷二酮类、DPP-4抑制剂、SGLT-2抑制剂相比风险亦显著降低。

核心结论

  • 在2型糖尿病患者中,GLP-1受体激动剂使用与胃肠道癌症风险降低相关,提示其在降糖和减重之外可能具有癌症保护获益。

研究设计与样本

  • 使用TriNetX研究网络开展的回顾性队列研究,比较GLP-1受体激动剂新使用者与其他降糖药使用者的胃肠道癌症风险。
  • 对人口学因素、社会经济因素、家族史、生活方式因素和癌症风险因素进行了倾向性评分匹配。
  • 主要结局为肥胖相关胃肠道癌症的发病率,次要结局为各具体癌症类型的发病率。

主要发现

  • 与所有其他降糖药相比,GLP-1受体激动剂使用与整体胃肠道癌症风险显著降低相关:胰岛素aHR 0.29(95%CI 0.23,0.37),二甲双胍aHR 0.84(95%CI 0.71,0.99),磺脲类aHR 0.71(95%CI 0.62,0.80),噻唑烷二酮类aHR 0.86(95%CI 0.74,0.99),DPP-4抑制剂aHR 0.80(95%CI 0.70,0.91),SGLT-2抑制剂aHR 0.80(95%CI 0.68,0.96)。
  • 与胰岛素治疗相比保护作用最为明显,所有具体癌症类型均显示显著风险降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Although benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been demonstrated in treatment of type 2 diabetes and weight management, their potential role in cancer prevention remains inadequately explored. METHODS: Using the TriNetX Research Network, we conducted a retrospective cohort study comparing new users of GLP-1RAs with users of other glucose-lowering medications. Propensity score matching was performed for demographic factors, socioeconomic factors, family history, lifestyle factors and cancer risk factors. The primary outcome was the incidence of obesity-related gastrointestinal cancers, and secondary outcomes were the incidence of individual cancer types. RESULTS: Using adjusted HRs (aHRs), GLP-1RA use was found to be associated with a significantly lower risk of overall gastrointestinal cancer compared with all other glucose-lowering medications (insulin: aHR 0.29; 95% CI 0.23, 0.37; metformin: aHR 0.84; 95% CI 0.71, 0.99; sulfonylureas: aHR 0.71; 95% CI 0.62, 0.80; thiazolidinediones: aHR 0.86; 95% CI 0.74, 0.99; dipeptidyl peptidase-4 inhibitors: aHR 0.80; 95% CI 0.70, 0.91; sodium-glucose cotransporter-2 inhibitors: aHR 0.80; 95% CI 0.68, 0.96). The protective effect was most pronounced compared with insulin therapy, with significant risk reductions across all individual cancers. CONCLUSIONS/INTERPRETATION: GLP-1RA use is associated with a reduced risk of gastrointestinal cancers in individuals with type 2 diabetes. These findings suggest potential cancer-protective benefits of GLP-1RAs beyond their established roles in glycaemic management and weight reduction.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kuo CC, Chuang MH, Li CH, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes. Diabetologia. 2025. PMID: 40471238. doi:10.1007/s00125-025-06453-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。